Compare Halliburton Company (HAL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halliburton Company vs State Street SPDR S&P Biotech ETF — how do they compare? Halliburton Company trades at $32.59 (market cap $27.14B), while State Street SPDR S&P Biotech ETF trades at $153.1 (market cap $10.11B). The key difference: Halliburton Company is far larger — about 2.7× State Street SPDR S&P Biotech ETF's market cap, and Halliburton Company pays a 2.09% dividend while State Street SPDR S&P Biotech ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halliburton Company for 89 Days and State Street SPDR S&P Biotech ETF for 37 Days on average.
| HAL | XBI | |
|---|---|---|
Market Cap | $27.14B | $10.11B |
Volume | 11,258,156 | 12,903,266 |
Sector | Energy | Broad Market / Factor |
52-Week High | $42.98 | $169.55 |
52-Week Low | $21.82 | $104.99 |
Typical Hold Time | 89 Days | 37 Days |
Enterprise Value | $33.29B | — |
Dividend Yield | 2.09% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Halliburton (HAL) trades at $31.75, down 2.96% on the day, reflecting near-term bearish technical signals despite strong analyst support. The stock shows solid fundamentals with a P/E of 17.05 and consistent earnings beats in recent quarters. Recent news highlights expansion in Venezuela and a new contract in Cyprus, positioning the company for growth in international energy markets. Cash flow trends indicate variability, with 2025 net cash flow negative but projected to turn positive in 2026.
The outlook for HAL is cautiously optimistic, driven by international contracts and analyst consensus pointing to significant upside with a $43.11 price target. Key risks include oil price volatility and execution challenges in new markets. Investment opportunity lies in the company's strategic expansions and robust profitability metrics, though investors should weigh macroeconomic factors affecting the energy sector.
XBI trades at $153.34, up 2.07% today, but faces bearish technical signals with 17 sell indicators versus 4 buys. The ETF's modified equal-weight structure provides exposure to over 150 biotech companies, benefiting from recent M&A activity and positive clinical trial catalysts. Current price sits near resistance at $154, with support at $147.
Biotech sector optimism is growing with cancer vaccine breakthroughs and improved capital access, though XBI's 0.35% expense ratio is higher than broader healthcare ETFs. Key risks include sector volatility and regulatory uncertainty, while analyst consensus remains neutral with 100% hold rating.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Halliburton Company
Halliburton is one of the three largest oilfield service firms in the world, offering superior expertise in a number of business lines, including completion fluids, wireline services, cementing, and countless others. It's the number one pressure pumper in North America, and has been a leading innovator in hydraulic fracturing over the last two decades.
Read more on HAL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
